The Scripps Research Institute

University of Florida Research Foundation Inc

The State University of New York

Chao Wang

Thomas D Bannister

John L Cleveland

Hui Wang

Agnieszka B Bialkowska

Vincent W Yang

The present disclosure provides compounds of formula (I), as described herein, their pharmaceutically acceptable salts, and their pharmaceutical compositions, which are effective in reducing the expression level of KLF5 or EGR1 in a living cell, and for the treatment of tumors and colorectal cancer in a human patient.

Small molecules for cancer therapy that reduce the expression of transcription factors KLF5 and EGR-1

The invention provides compounds effective as inhibitors of monocarboxylate transporters such as MCT1 and MCT4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on MCT1, MCT4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type II diabetes.

Pteridine dione monocarboxylate transporter inhibitors

Chromenone inhibitors of monocarboxylate transporters

Growing community of inventors

Palm Beach Gardens, FL, United States of America

Chao Wang